For quotations, please use our online quotation form, and you may also contact us by
sales@neoscientific.com
+1-888.733.6849
+1-617.299.7367 (Int’l)
+1-888.733.6849
+1-617.299.7367 (Int’l)
Reactivity | Human Mouse |
Tested applications | WB IHC |
Recommended Dilution | WB 1:500 - 1:2000 IHC 1:50 - 1:200 |
Calculated MW | 33kDa |
Observed MW | Refer to Figures |
Immunogen | Recombinant protein of human TNFSF10 |
Storage Buffer | Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
Concentration | b |
Synonym | APO2L; Apo-2L; CD253; TL2; TRAIL |
Western blot analysis of extracts of mouse kidney cells, using TNFSF10 antibody.
Immunohistochemistry of paraffin-embedded human colon carcinoma using TNFSF10 antibody at dilution of 1:200 (40x lens).
Immunohistochemistry of paraffin-embedded human prostate using TNFSF10 antibody at dilution of 1:200 (40x lens).
Immunohistochemistry of paraffin-embedded mouse kidney using TNFSF10 antibody at dilution of 1:200 (40x lens).
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18).
N/A